• 1
    Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med. 1985; 312: 14651472.
  • 2
    Fisher B,Wolmark N,Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988; 80: 2129.
  • 3
    NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 14441450.
  • 4
    Douglass HOJr,Moertel CG,Mayer RJ, et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986; 315: 12941295.
  • 5
    Tepper JE,O'Connell M,Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol. 2002; 20: 17441750.
  • 6
    Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. J Clin Oncol. 1992; 10: 549557.
  • 7
    O'Connell MJ,Martenson JA,Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994; 331: 502507.
  • 8
    Krook JE,Moertel CG,Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991; 324: 709715.
  • 9
    Cronin DP,Harlan LC,Potosky AL,Clegg LX,Stevens JL,Mooney MM. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006; 101: 23082318.
    Direct Link:
  • 10
    Dharma-Wardene MW,de Gara C,Au HJ,Hanson J,Hatcher J. Ageism in rectal carcinoma? Treatment and outcome variations. Int J Gastrointest Cancer. 2002; 32: 129138.
  • 11
    Potosky AL,Harlan LC,Kaplan RS,Johnson KA,Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20: 11921202.
  • 12
    Neugut AI,Fleischauer AT,Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002; 20: 26432650.
  • 13
    Schrag D,Gelfand SE,Bach PB,Guillem J,Minsky BD,Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results—Medicare. J Clin Oncol. 2001; 19: 37123718.
  • 14
    Miller RC,Martenson JA,Sargent DJ,Kahn MJ,Krook JE. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys. 1998; 41: 593598.
  • 15
    Kollmorgen CF,Meagher AP,Wolff BG,Pemberton JH,Martenson JA,Illstrup DM. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg. 1994; 220: 676682.
  • 16
    Dobie SA,Baldwin LM,Dominitz JA,Matthews B,Billingsley K,Barlow W. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006; 98: 610619.
  • 17
    GreeneFL,PageDL,FlemingID, et al., eds. AJCC cancer staging manual.6th ed. New York: Springer-Verlag; 2002.
  • 18
    Virnig BA,Warren JL,Cooper GS,Klabunde CN,Schussler N,Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002; 40(8 suppl): IV-4954.
  • 19
    Du X,Freeman JL,Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. Surveillance, Epidemiology and End Results. J Clin Epidemiol. 1999; 52: 463470.
  • 20
    Lamont EB,Lauderdale DS,Schilsky RL,Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002; 40: 201211.
  • 21
    Warren JL,Harlan LC,Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40(8 suppl): IV-5561.
  • 22
    O'Connell MJ,Laurie JA,Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998; 16: 295300.
  • 23
    Charlson ME,Pompei P,Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 24
    Romano PS,Roos LL,Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 10751079; discussion, 1081–1090.
  • 25
    Morrill R,Cromartie J,Hart LG. Metropolitan, urban, and rural commuting areas: toward a better depiction of the US settlement system. Urban Geogr. 1999; 20: 727748.
  • 26
    WWAMI Rural Health Research Center. Rural-urban commuting area codes (version 2.0). Available at: Accessed February 20, 2007.
  • 27
    Zhang J,Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998; 280: 16901691.
  • 28
    Baxter NN,Rothenberger DA,Morris AM,Bullard KM. Adjuvant radiation for rectal cancer: do we measure up to the standard of care? An epidemiologic analysis of trends over 25 years in the United States. Dis Colon Rectum. 2005; 48: 915.
  • 29
    Minsky BD,Cohen AM,Kemeny N, et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol. 1992; 10: 12181224.
  • 30
    Osti MF,Valeriani M,Masoni L,Tombolini V,Enrici RM. Neoadjuvant chemoradiation for locally advanced carcinoma of the rectum. Tumori. 2004; -309.
  • 31
    Pahlman L,Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg. 1990; 211: 187195.
  • 32
    Ahmad NR,Marks G,Mohiuddin M. High-dose preoperative radiation for cancer of the rectum: impact of radiation dose on patterns of failure and survival. Int J Radiat Oncol Biol Phys. 1993; 27: 773778.
  • 33
    Sauer R,Becker H,Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 17311740.
  • 34
    Valero G,Lujan JA,Hernandez Q, et al. Neoadjuvant radiation and chemotherapy in rectal cancer does not increase postoperative complications. Int J Colorectal Dis. 2003; 18: 495499.
  • 35
    Kapiteijn E,Marijnen CA,Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345: 638646.
  • 36
    Heald RJ,Moran BJ,Ryall RD,Sexton R,MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg. 1998; 133: 894899.
  • 37
    Enker WE,Thaler HT,Cranor ML,Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995; 181: 335346.
  • 38
    Bulow S,Christensen IJ,Harling H,Kronborg O,Fenger C,Nielsen HJ. Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg. 2003; 90: 974980.
  • 39
    Habr-Gama A,Perez RO,Kiss DR, et al. Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations. Hepatogastroenterology. 2004; 51: 17031707.
  • 40
    Tepper JE,O'Connell MJ,Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001; 19: 157163.
  • 41
    Gunderson LL,Sargent DJ,Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004; 22: 17851796.
  • 42
    Greene FL,Stewart AK,Norton HJ. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol. 2004; 22: 17781784.
  • 43
    Jeong SY,Chessin DB,Schrag D,Riedel E,Wong WD,Guillem JG. Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2005; 97: 17051706; author reply 1706–1707. Comment on:J Natl Cancer Inst.2004;96:1408–1409 andJ Natl Cancer Inst.2004;96:1420–1425.
  • 44
    Guillem JG,Chessin DB,Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005; 241: 829836; discussion 836–828.